Clinical and Experimental Metastasis This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Extensive diagnostic work-up for patients with carcinoma of unknown primary
AbstractPatients with carcinoma of unknown primary (CUP) present with metastatic disease without an identified primary tumour. The unknown site of origin makes the diagnostic work-up and treatment challenging. Since little information is available regarding diagnostic work-up and treatment in daily practice, we collected and analysed these in a patient cohort with regard to the recommendations of the national CUP guideline. Data of 161 patients diagnosed with CUP in 2014 or 2015 were extracted from the Netherlands Cancer Registry (NCR) and supplemented with diagnostic work-up information from patient files and analysed. Pa...
Source: Clinical and Experimental Metastasis - January 30, 2021 Category: Cancer & Oncology Source Type: research

The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review
In conclusion, CRS with HIPEC for PDAC-derived PM appears to be safe, conferring the same postoperative morbidity and mortality as reported on non-pancreatic malignancies. In highly selected patients, it could be considered for short-term disease control. However, long-term survival remains poor. The addition of prophylactic HIPEC for resectable PDAC cannot be recommended. (Source: Clinical and Experimental Metastasis)
Source: Clinical and Experimental Metastasis - January 24, 2021 Category: Cancer & Oncology Source Type: research

Integrating stereotactic body radiation therapy (SBRT) and systemic treatments in oligoprogressive prostate cancer: new evidence from the literature
AbstractRecent findings from literature evidenced that metastatic prostate cancer often shows heterogeneous response to therapy, with persistent sensibility to systemic treatments after biochemical, clinical, or radiographic progression. This highlights the advantage of integrated approaches in which local ablative treatments (e.g., stereotactic body radiation therapy) could prolong clinical benefit of systemic therapies beyond oligo-progression. Of course, development of predictive biomarker could be helpful in order to select patients who could much benefit from this treatment strategy. Circulating tumor cell detection a...
Source: Clinical and Experimental Metastasis - January 20, 2021 Category: Cancer & Oncology Source Type: research

Systematic review of stereotactic body radiotherapy for nodal metastases
AbstractThe aim of this analysis was to assess the efficacy of stereotactic body radiotherapy (SBRT) in terms of local control (LC) and progression-free survival (PFS) in patients with lymph node metastases (NMs) from solid tumors. A systematic literature search from the earliest date to July 25th, 2019 was performed following PRISMA guidelines. Papers reporting LC and/or PFS of NMs using SBRT (<  10 fractions) were selected. The clinical outcomes rates were pooled by means of a random or fixed-effect model. Twenty-nine studies were eligible (969 patients: 938 (LC) and 698 (PFS)). LC and PFS results were reported in 2...
Source: Clinical and Experimental Metastasis - January 16, 2021 Category: Cancer & Oncology Source Type: research

Survival outcome and prognostic factors for colorectal cancer with synchronous bone metastasis: a population-based study
AbstractPrognostic factors of synchronous bone metastatic colorectal cancer (CRC) are still undetermined. We aimed to investigate survival outcome and prognostic factors of patients with synchronous bone metastatic CRC. Information of patients with synchronous bone metastatic CRC were obtained from the Surveillance, Epidemiology, and End Results (SEER) and West China Hospital (WCH) databases. Cases from SEER database composed construction cohort, while cases from WCH database were used as validation cohort. A novel nomogram was constructed to predict individual survival probability based on Cox regression model. The perfor...
Source: Clinical and Experimental Metastasis - January 9, 2021 Category: Cancer & Oncology Source Type: research

EMT-independent detection of circulating tumor cells in human blood samples and pre-clinical mouse models of metastasis
AbstractCirculating tumor cells (CTCs) present an opportunity to detect/monitor metastasis throughout disease progression. The CellSearch ® is currently the only FDA-approved technology for CTC detection in patients. The main limitation of this system is its reliance on epithelial markers for CTC isolation/enumeration, which reduces its ability to detect more aggressive mesenchymal CTCs that are generated during metastasis via epithe lial-to-mesenchymal transition (EMT). This Technical Note describes and validates two EMT-independent CTC analysis protocols; one for human samples using Parsortix® and one for mouse samples...
Source: Clinical and Experimental Metastasis - January 7, 2021 Category: Cancer & Oncology Source Type: research

Modeling breast cancer survival and metastasis rates from moderate-sized clinical data
AbstractPredicting time-dependent survival probability of a breast cancer patient using information such as primary tumor size, grade, node spread status, and patient age at the time of surgery can be of immense help in managing life expectations and strategizing postoperative treatment. However, for moderate-sized clinical datasets the application of standard Kaplan –Meier theory to determine survival probability as a function of multiple cofactors can become challenging when continuous variables like tumor diameter and survival time are segmented into a large number of narrow intervals, a problem commonly termed the cu...
Source: Clinical and Experimental Metastasis - January 3, 2021 Category: Cancer & Oncology Source Type: research

Hypofractionated frameless gamma knife radiosurgery for large metastatic brain tumors
AbstractHypofractionated stereotactic radiosurgery has become an alternative for metastatic brain tumors (METs). We aimed to analyze the efficacy and safety of frameless hypofractionated Gamma Knife radiosurgery (hfGKRS) in the management of unresected, large METs. All patients who were managed with hfGKRS for unresected, large METs (> 4 cm3) between June 2017 and June 2020 at a single center were reviewed in this retrospective study. Local control (LC), progression-free survival (PFS), overall survival (OS), and toxicities were investigated. A total of 58 patients and 76 METs with regular follow-up were analyzed. LC ra...
Source: Clinical and Experimental Metastasis - January 3, 2021 Category: Cancer & Oncology Source Type: research

Improved detection of sentinel lymph node metastases allows reliable intraoperative identification of patients with extended axillary lymph node involvement in early breast cancer
AbstractBackgroundAn improved procedure that allows accurate detection of negative sentinel lymph node (SLN) and of SLN macrometastases during surgery would be highly desirable in order to protect patients from further surgery and to avoid unnecessary costs. We evaluated the accuracy of an intraoperative procedure that combines touch imprint cytology (TIC) and subsequent frozen section (FS) analysis. 2276 SLNs from 1072 patients with clinical node-negative early breast cancer were evaluated during surgery using TIC. Only cytologically-positive SLN were subsequently analysed with a single FS, preserving cytologically-negati...
Source: Clinical and Experimental Metastasis - November 29, 2020 Category: Cancer & Oncology Source Type: research

Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer
Abstract20 –40% of lung cancer patients develop bone metastasis (BM) with significantly decreased overall survival. Currently, BM is mainly diagnosed by computerized tomography (CT) scan or magnetic resonance imaging (MRI) when symptom develops. Novel biomarkers with higher prediction value of BM are needed. Plasma-derived exosomal microRNAs had been isolated and sequenced of total 30 non-small cell lung cancer (NSCLC) patients including 16 with bone metastasis and 14 without bone metastasis. Hierarchical clustering based on the total miRNA profile can clearly separate cancer patients and healthy indiv iduals (H), but no...
Source: Clinical and Experimental Metastasis - November 24, 2020 Category: Cancer & Oncology Source Type: research

Management and prognostic analysis of patients with gestational trophoblastic neoplasia (GTN) in FIGO stage IV and its special type
AbstractGTN is a group malignant diseases from placental trophoblastic cells. There are very few cases of GTN with FIGO (International Federation of Gynecology and Obstetrics) stage IV all over the world, and the special types (patients with metastatic lesions and with no evidence of GTN neither in genitalia nor in lungs) have rarely been reported. It is necessary to conduct large retrospective studies aimed at exploring the diagnosis, treatment and outcomes of this disease. In this retrospective study, 716 patients with GTN were treated at Zhejiang University School of Medicine Women ’s Hospital between January 1999 and...
Source: Clinical and Experimental Metastasis - November 20, 2020 Category: Cancer & Oncology Source Type: research

Electrochemotherapy of skin metastases from breast cancer: a systematic review
AbstractSkin metastases occur in 5 –30% of breast cancer (BC) patients. Standard treatments include systemic therapies (chemotherapy, endocrine therapy, and immunotherapy) and local treatments (surgery and radiotherapy). Electrochemotherapy (ECT) could be another option in this setting based on preclinical and clinical studies. Aim of this review was to analyze the available evidence on ECT in skin metastases from BC. Studies reporting on ECT in skin metastases from BC were included in this review. Studies not reporting toxicity or tumor response or not reporting results separately from other primary cancers were exclude...
Source: Clinical and Experimental Metastasis - November 12, 2020 Category: Cancer & Oncology Source Type: research

Is survival really better after repeated lung metastasectomy?
AbstractSeveral groups have observed that average survival time after a second lung metastasectomy is longer than after a first metastasectomy. The randomised controlled trial Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) found no survival benefit from lung metastasectomy. In fact, median survival was longer, and four-year overall survival was higher, in the control group than in those randomly assigned to metastasectomy, although not significantly so. The illusion of benefit is because survival without metastasectomy has been assumed to be near zero, as stated in Society of Thoracic Surgeons ’ Expert Consensus...
Source: Clinical and Experimental Metastasis - October 29, 2020 Category: Cancer & Oncology Source Type: research

The rise of metastatic bone disease in Ireland
AbstractTo describe the expected rise of metastatic bone disease in Ireland, the relative primary types, and the locations of spread within the skeleton. This was a population-based epidemiological study using cancer registry data. We included patients with known metastatic cancer to bone, within 1  year of the primary diagnosis, during the years 1994 to 2012 inclusive. Our main outcome measures were age-specific, gender-specific and age-standardised incidence rates of bone metastasis, primary types and metastatic location within the skeleton. There were 14,495 recognised cases of bone metast asis in Ireland, 1994–2012 ...
Source: Clinical and Experimental Metastasis - October 24, 2020 Category: Cancer & Oncology Source Type: research

Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer
In this study, we performed a proteome analysis of three recurrent liver metastases of a single CRC patient by mass spectrometry. Despite surgical resection of the primary CRC and adjuvant chemotherapy plus cetuximab treatment, the patient developed three metachronous CRLM which occurred con secutively after 9, 21 and 31 months. We identified a set of 1132 proteins expressed in the three metachronous CRLM, of which 481 were differentially regulated, including 81 proteins that were associated with the extracellular matrix (ECM). 56 ECM associated proteins were identified as upregulated in the third metastasis, 26 (46%) of ...
Source: Clinical and Experimental Metastasis - October 24, 2020 Category: Cancer & Oncology Source Type: research